Table 1 Model inputs
Parameter | Point estimate | Range | Source |
|---|---|---|---|
Candidemia risk and mortality | Â | Â | Â |
   Risk of candidemia | 0.140 | 0.048 to 0.283 | See Table S1 in Additional data file 1 |
   Risk of CK/CG among candidemia | 0.148 | 0.132 to 0.361 | See Table S2 in Additional data file 1 |
   Candidemia attributable mortality | 0.4 | 0.2 to 0.8 | Golan and colleagues [22] |
   Mortality reduction with appropriate empiric therapy | 0.48 | 0.35 to 0.65 | Morrell and colleagues [12] (inverse) |
Evaluation and treatment | Â | Â | Â |
   Days of empiric treatment until availability of C&S results | 3 | 2 to 4 | Assumption |
   Total duration of appropriate treatment (days) | 10 | 7 to 14 | Guideline recommendations of 14 days reduced to 10 days to account for mortalities |
   Days of antibiotic treatment if switched from MIC to FLU in response to C&S | 7 | 4 to 10 | Total duration of appropriate treatment – Days of empiric treatment until availability of C&S results |
   Days of antibiotic treatment if switched from FLU to MIC in response to C&S | 10 | 7 to 14 | Total duration of appropriate treatment |
Cost of antibiotics | Â | Â | Â |
   MIC ($/100 mg daily IV) | $100 | $80 to 120 | WHC Pharmacy |
   FLU ($/400 mg daily IV) | $12 | $10 to 14 | WHC Pharmacy |
   FLU ($/400 mg single loading dose on day 1) | $12 | $10 to 14 | WHC Pharmacy |
Life expectancy, QALY adjustment and lifetime costs | Â | Â | Â |
   Median age (years) | 64 | 48 to 80 | Median from Table S1 in Additional data file 1; range is +/- 25% median |
   Life expectancy (years) | 17.4 | 13.0 to 21.4 | Actuarial tables from the US Social Security Administration [24]; for men; range is +/-25% |
   Relative risk of death | 0.51 | 0.49 to 0.59 | Quartin and colleagues [25] |
   QALY adjustment | 0.64 | 0.44 to 0.80 | |
   Age-specific annual healthcare costs/survivor in 2001 $US* | $16,446 | $12,335 to $20,558 | Shorr and colleagues [29] |
   Annual discount rate | 3% | 0 to 6% | Weinstein and colleagues [19] |